有创机械通气期间的应激性溃疡预防
该国际随机试验纳入68个ICU中接受有创机械通气的危重成人4821例,随机接受静脉泮托拉唑40 mg每日一次或匹配安慰剂。主要疗效终点为90天时ICU内临床重要上消化道出血,泮托拉唑组25/2385例(1.0%)vs 安慰剂组84/2377例(3.5%),HR 0.30(95%CI 0.19–0.47),P<0.001。主要安全终点90天全因死亡为泮托拉唑组696/2390例(29.1%)vs 安慰剂组734/2379例(30.9%),HR 0.94(95%CI 0.85–1.04),P=0.25。患者重要出血在泮托拉唑组减少,其余次要结局两组相似。
要点
- 接受有创机械通气的危重成人中,静脉泮托拉唑40 mg每日一次较安慰剂显著降低ICU内临床重要上消化道出血(1.0% vs 3.5%,HR 0.30;95%CI 0.19–0.47;P<0.001)。
- 90天全因死亡泮托拉唑组29.1% vs 安慰剂组30.9%,HR 0.94(95%CI 0.85–1.04),P=0.25,无显著差异。
- 患者重要出血在泮托拉唑组减少,其余经多重性校正的次要结局(呼吸机相关性肺炎、艰难梭菌感染等)两组相似。
- 该试验为国际随机试验,共68个ICU、4821例接受有创机械通气的危重成人随机分组。
适用人群与场景
- 接受有创机械通气的危重成人,国际多中心ICU人群(68个ICU)。
处置流程与药物剂量
- 静脉泮托拉唑40 mg每日一次,与匹配安慰剂对照,用于接受有创机械通气危重成人的应激性溃疡预防。
研究设计与关键结果
- 国际随机试验,4821例接受有创机械通气的危重成人随机分组,68个ICU参与。
- 主要疗效终点ICU内临床重要上消化道出血:泮托拉唑组25/2385例(1.0%)vs 安慰剂组84/2377例(3.5%),HR 0.30(95%CI 0.19–0.47),P<0.001。
- 主要安全终点90天全因死亡:泮托拉唑组696/2390例(29.1%)vs 安慰剂组734/2379例(30.9%),HR 0.94(95%CI 0.85–1.04),P=0.25。
- 患者重要出血在泮托拉唑组减少;其余经多重性校正的次要结局(呼吸机相关性肺炎、艰难梭菌感染)两组相似。
证据类型、等级与局限
- 证据类型:国际随机对照试验(REVISE,ClinicalTrials.gov NCT03374800)。
- 资助:Canadian Institutes of Health Research等。
对床旁实践的改变
- 在接受有创机械通气的危重成人中,静脉泮托拉唑40 mg每日一次可降低ICU内临床重要上消化道出血风险,且未增加90天全因死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether proton-pump inhibitors are beneficial or harmful for stress ulcer prophylaxis in critically ill patients undergoing invasive ventilation is unclear.
METHODS: In this international, randomized trial, we assigned critically ill adults who were undergoing invasive ventilation to receive intravenous pantoprazole (at a dose of 40 mg daily) or matching placebo. The primary efficacy outcome was clinically important upper gastrointestinal bleeding in the intensive care unit (ICU) at 90 days, and the primary safety outcome was death from any cause at 90 days. Multiplicity-adjusted secondary outcomes included ventilator-associated pneumonia, Clostridioides difficile infection, and patient-important bleeding.
RESULTS: A total of 4821 patients underwent randomization in 68 ICUs. Clinically important upper gastrointestinal bleeding occurred in 25 of 2385 patients (1.0%) receiving pantoprazole and in 84 of 2377 patients (3.5%) receiving placebo (hazard ratio, 0.30; 95% confidence interval [CI], 0.19 to 0.47; P<0.001). At 90 days, death was reported in 696 of 2390 patients (29.1%) in the pantoprazole group and in 734 of 2379 patients (30.9%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.85 to 1.04; P = 0.25). Patient-important bleeding was reduced with pantoprazole; all other secondary outcomes were similar in the two groups.
CONCLUSIONS: Among patients undergoing invasive ventilation, pantoprazole resulted in a significantly lower risk of clinically important upper gastrointestinal bleeding than placebo, with no significant effect on mortality. (Funded by the Canadian Institutes of Health Research and others; REVISE ClinicalTrials.gov number, NCT03374800.).
参考来源
- Cook D, Deane A, Lauzier F, et al. Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation. N Engl J Med. 2024. PMID: 38875111. doi:10.1056/NEJMoa2404245
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。